influenza
viru
infect
remain
seriou
threat
global
health
world
economi
annual
epidem
result
high
number
hospit
estim
million
case
sever
diseas
death
global
higher
mortal
rate
possibl
pandem
wright
et
al
given
emerg
antivir
drugresist
short
treatment
window
antivir
lack
crossprotect
vaccin
unmet
medic
need
new
therapeut
option
effect
treat
influenza
infect
three
type
influenza
virus
b
c
caus
diseas
human
influenza
b
respons
frequent
season
epidem
howev
influenza
infect
account
major
hospit
type
caus
pandem
wright
et
al
influenza
subtyp
two
major
surfac
protein
hemagglutinin
ha
neuraminidas
na
ha
main
target
neutral
antibodi
induc
infect
vaccin
globular
ha
head
domain
mediat
bind
sialic
acid
receptor
ha
stem
mediat
subsequ
fusion
viral
cellular
membran
trigger
endosom
low
ph
skehel
wiley
genet
influenza
subtyp
ha
form
two
structur
antigen
distinct
group
nobusawa
et
al
russel
et
al
addit
two
new
ha
analog
recov
bat
includ
classif
tong
et
al
tong
et
al
current
ha
subtyp
associ
human
diseas
virus
contain
associ
sporad
human
infect
due
direct
transmiss
avian
speci
major
influenza
viru
neutral
antibodi
elicit
vaccin
infect
bind
globular
head
ha
recogn
homolog
strain
within
given
subtyp
russel
et
al
antibodi
neutral
viru
infect
block
sialic
acid
receptor
bind
either
directli
knossow
skehel
schmidt
et
al
interact
receptor
bind
site
tip
molecul
indirectli
project
bind
site
therebi
render
inaccess
fleuri
et
al
xiong
et
al
antibodi
involv
select
virus
variant
process
antigen
drift
necessit
annual
redevelop
influenza
vaccin
past
year
sever
laboratori
describ
new
class
influenzaneutr
antibodi
target
conserv
site
ha
stem
show
differ
level
crossreact
toward
group
corti
et
al
sui
et
al
throsbi
et
al
wrammert
et
al
group
dunand
et
al
ekiert
et
al
friesen
et
al
tan
et
al
group
virus
corti
et
al
dreyfu
et
al
nakamura
et
al
wu
et
al
antistem
antibodi
less
potent
direct
viral
neutral
compar
antihead
antibodi
shown
induc
potent
antibodydepend
cellular
cytotox
adcc
infect
cell
vitro
vivo
corti
et
al
dilillo
et
al
dilillo
et
al
antihead
antibodi
less
effect
mediat
adcc
gener
human
antibodi
respons
ha
stem
region
frequent
group
compar
group
domin
antibodi
pappa
et
al
sui
et
al
wrammert
et
al
although
subdomin
group
stem
respons
shown
recal
heterolog
boost
new
pandem
viru
corti
et
al
wrammert
et
al
antibodi
respons
ha
stem
region
group
less
frequent
possibl
due
presenc
conserv
glycan
bound
may
shield
access
conserv
site
ha
stem
lack
exposur
heterolog
group
virus
ie
new
pandem
virus
final
antibodi
capabl
react
ha
stem
region
group
subtyp
extrem
rare
usual
show
complet
coverag
subtyp
hypothes
broadli
crossreact
antibodi
might
potenti
therapeut
agent
studi
mechan
action
epitop
specif
ontogeni
could
also
inform
design
crossprotect
influenza
viru
vaccin
corti
lanzavecchia
yewdel
problem
relat
develop
antistem
antibodi
immunotherapeut
variabl
neutral
potenc
virus
belong
differ
subtyp
exist
natur
escap
mutant
view
limit
group
group
antibodi
isol
far
search
antibodi
capabl
potent
neutral
group
influenza
virus
within
narrow
rang
antibodi
concentr
studi
isol
optim
antibodi
name
exhibit
unpreced
breadth
potenc
abl
neutral
divers
panel
repres
virus
span
year
antigen
evolut
unlik
broadli
neutral
stemreact
antibodi
uniqu
use
rare
vh
carri
low
level
somat
mutat
crystallograph
analysi
fab
alon
complex
ha
protein
reveal
bind
highli
conserv
epitop
markedli
differ
structur
character
stemreact
neutral
antibodi
character
uniqu
epitop
breadth
potenc
neutral
exhibit
support
develop
immunotherapi
influenza
virusinfect
human
four
broadli
reactiv
antibodi
isol
memori
b
cell
select
donor
base
influenza
ha
protein
crossreact
previous
report
traggiai
et
al
pappa
et
al
antibodi
belong
lineag
carri
gene
segment
figur
reconstruct
genealog
tree
lineag
produc
unmut
common
ancestor
uca
four
clonal
deriv
antibodi
three
antibodi
repres
evolutionari
branch
point
bp
lineag
figur
purifi
antibodi
test
neutral
activ
multipl
virus
differ
group
subtyp
figur
interestingli
uca
antibodi
exhibit
neutral
activ
group
virus
group
virus
albeit
lower
potenc
compar
mutat
antibodi
note
first
bp
gain
neutral
activ
toward
earli
group
virus
two
antibodi
ie
lineag
acquir
neutral
activ
group
virus
two
independ
pathway
somat
mutat
analysi
extend
lineag
previous
describ
antibodi
crossneutr
group
group
virus
corti
et
al
isol
five
addit
antibodi
lineag
allow
reconstruct
complex
genealog
tree
figur
similarli
observ
lineag
antibodi
exhibit
neutral
activ
group
virus
evolv
two
independ
pathway
somat
mutat
led
group
antibodi
group
crossreact
antibodi
taken
togeth
find
suggest
lineag
uca
initi
select
group
viru
develop
branch
point
character
crossreact
toward
limit
number
group
virus
point
final
antibodi
may
select
bind
group
eg
group
eg
result
consist
model
develop
crossreact
group
antibodi
start
group
select
boost
group
antibodi
chosen
lead
base
potenc
breadth
low
somat
mutat
vitro
optim
parsimoni
mutagenesi
complementar
determin
region
cdr
combin
revers
unnecessari
somat
mutat
framework
optim
focus
affin
bind
result
improv
fab
affin
ha
ha
protein
determin
surfac
plasmon
reson
respect
tabl
result
antibodi
name
vh
vl
sequenc
shown
figur
compar
side
side
parent
antibodi
bind
neutral
larg
panel
influenza
virus
show
higher
bind
activ
compar
group
ha
protein
subtyp
group
ha
protein
subtyp
mean
halfmaxim
effect
concentr
versu
respect
figur
tabl
addit
investig
bind
remain
includ
pandem
strain
two
recent
identifi
ha
analog
recov
bat
tong
et
al
tong
et
al
flow
cytometr
analysi
cellsurfac
express
figur
note
bound
gain
reactiv
ha
parent
antibodi
examin
higher
potenc
breadth
bind
activ
compar
translat
potent
broad
antivir
activ
measur
neutral
activ
antibodi
variant
mdck
cell
divers
panel
season
virus
emerg
potenti
epidem
virus
isol
period
span
year
season
influenza
virus
test
neutral
median
valu
respect
result
nearli
increas
overal
potenc
figur
howev
antibodi
exhibit
compar
activ
neutral
group
group
virus
similar
valu
virus
respect
figur
increas
overal
activ
compar
also
appar
test
nonseason
influenza
virus
includ
virus
isol
recent
human
infect
neutral
virus
overal
median
rang
versu
median
rang
figur
result
indic
optim
result
increas
potenc
neutral
abil
bind
ha
subtyp
influenza
virus
extend
evalu
directli
compar
vitro
neutral
activ
breadth
previous
publish
crossgroup
neutral
mab
corti
et
al
dreyfu
et
al
nakamura
et
al
use
divers
panel
season
nonseason
influenza
strain
group
group
figur
report
previous
antibodi
neutral
group
group
virus
although
exhibit
distinct
differ
potenc
breadth
among
antibodi
test
one
demonstr
neutral
activ
virus
test
median
rang
fail
neutral
human
viru
unabl
neutral
contemporari
human
isol
incap
neutral
viru
virus
contemporari
viru
highest
concentr
test
addit
better
overal
breadth
neutral
exhibit
equal
greater
neutral
potenc
crossreact
monoclon
antibodi
median
compar
respect
nonneutr
virus
exclud
analysi
crosssubtyp
neutral
antibodi
report
date
inhibit
hamedi
membran
fusion
activ
vitro
corti
et
al
dreyfu
et
al
nakamura
et
al
activ
fusion
requir
cleavag
precursor
exposur
cleav
ha
low
ph
endosom
assay
two
process
shown
inhibit
host
cell
proteas
cleavag
group
group
would
prevent
membran
fusion
figur
bind
cleav
ha
also
prevent
low
phinduc
conform
chang
requir
membran
fusion
stabil
prefus
conform
figur
addit
shown
mediat
lysi
infect
cell
human
primari
nk
cell
adcc
antibodydepend
cellular
phagocytosi
adcp
mdck
cell
express
human
monocytederiv
macrophag
complementdepend
cytotox
cdc
influenzainfect
mdck
cell
presenc
complement
figur
evalu
antivir
activ
mice
challeng
lethal
dose
three
differ
influenza
virus
awilson
smith
reassort
ahong
doserang
studi
conduct
administ
time
viru
challeng
mice
receiv
mgkg
surviv
challeng
mice
surviv
receiv
mgkg
respect
figur
consist
surviv
data
lung
viral
titer
significantli
reduc
compar
control
antibodytr
anim
administ
mgkg
figur
addit
observ
two
highest
dose
significantli
protect
lung
function
mice
compar
control
antibodi
measur
puls
oximetri
figur
evalu
therapeut
util
administ
differ
time
point
follow
infect
viru
dose
mgkg
surviv
rate
achiev
even
treatment
delay
day
post
infect
day
post
infect
figur
signific
surviv
benefit
also
seen
mgkg
dose
administ
day
post
infect
albeit
lower
surviv
rate
mgkg
tabl
treatment
mgkg
time
post
infect
result
significantli
decreas
viral
titer
compar
control
antibodi
treat
untreat
anim
clear
trend
greater
reduct
earlier
treatment
figur
investig
therapeut
potenti
determin
therapeut
window
treat
ferret
infect
highli
pathogen
avian
influenza
viru
studi
ferret
infect
intranas
treat
singl
intraven
iv
dose
mgkg
day
post
infect
also
use
compar
antiinfluenza
drug
oseltamivir
mgkg
twice
day
bid
figur
expect
control
anim
show
sign
infect
includ
fever
peak
day
post
infect
mortal
day
post
infect
figur
comparison
ferret
treat
oseltamivir
day
post
infect
complet
protect
treatment
delay
day
post
infect
provid
complet
protect
surviv
oseltamivir
partial
protect
anim
surviv
rate
respect
addit
treatment
result
period
fever
reduct
follow
administr
observ
oseltamivir
control
antibodytr
anim
figur
similar
efficaci
therapeut
window
result
seen
oseltamivir
treatment
compar
lethal
murin
model
figur
provid
insight
structur
basi
breadth
potenc
determin
structur
fab
fragment
complex
ha
protein
resolut
respect
figur
structur
ha
protein
complex
similar
apo
structur
determin
russel
et
al
xiong
et
al
make
similar
contact
bind
similar
orient
figur
fab
interact
one
protom
ha
trimer
overal
interact
buri
solvent
complex
respect
consist
high
bind
affin
tabl
contact
fusion
domain
ha
interact
three
region
central
hydrophob
groov
fusion
peptid
helix
specif
residu
compon
fusion
domain
figur
locat
complex
ha
protein
consist
vitro
assay
show
stabil
prefus
conform
inhibit
fusion
well
block
proteolyt
cleavag
ha
precursor
neighbor
subunit
figur
although
structur
complex
determin
intermedi
resolut
interfac
fab
wellord
electron
densiti
map
area
among
clearest
overal
complex
unbias
omit
electron
densiti
map
shown
figur
therefor
confid
descript
intermolecular
contact
hydrogen
bond
describ
text
regard
potenti
interact
howev
given
limit
defin
exact
geometri
interact
princip
contact
area
involv
three
cdr
minor
interact
figur
make
extens
contact
bottom
hydrophob
groov
helix
fusion
domain
compon
figur
insert
groov
made
residu
helix
fusion
peptid
bind
lower
posit
groov
interact
main
chain
residu
fusion
peptid
well
side
chain
figur
also
make
hydrophob
contact
fusion
peptid
figur
loop
interact
vh
germlineencod
residu
residu
fusion
peptid
figur
particular
almost
complet
protect
solvent
also
van
der
waal
interact
posit
within
hydrogen
bond
distanc
form
salt
bridg
also
contribut
polar
patch
antibodi
surfac
includ
final
interact
ntermin
region
helix
figur
hydrogen
bond
distanc
make
hydrophob
contact
aliphat
moieti
helix
side
chain
stack
helix
hydroxyl
group
hydrogen
bond
distanc
main
chain
fusion
peptid
epitop
recogn
highli
conserv
ha
protein
consist
antibodi
broad
activ
group
group
influenza
virus
figur
howev
membran
proxim
fusion
domain
group
group
distinct
structur
differ
glycosyl
statu
posit
could
potenti
affect
bind
antibodi
corti
et
al
ekiert
et
al
sui
et
al
complex
bulki
carbohydr
chain
attach
chang
orient
allow
antibodi
bind
observ
ha
complex
corti
et
al
anoth
notabl
featur
complex
ha
involv
aromat
stack
interact
interestingli
tyrosin
posit
conserv
across
ha
subtyp
arginin
could
engag
similar
stack
interact
although
leucin
lysin
glutamin
found
remain
ha
protein
could
interact
way
thu
high
similar
affin
react
suggest
differ
glycosyl
side
chain
make
minor
contribut
overal
energet
bind
figur
tabl
avail
highresolut
structur
fab
wellord
interfac
structur
complex
form
enabl
us
analyz
conform
chang
fab
upon
ha
bind
particularli
loop
loop
form
residu
undergo
larg
rigidbodi
rotat
pivot
around
figur
facilit
interact
ha
consequ
side
chain
move
insert
hydrophob
groov
epitop
near
addit
residu
restructur
averag
displac
apo
bound
form
reorient
side
chain
enabl
interact
complex
complex
form
helic
structur
place
hydrogen
bond
distanc
five
mutat
found
vitro
optim
direct
contact
ha
contain
within
cdr
loop
figur
mutat
residu
seen
stabil
conform
loop
region
adopt
complex
ha
parent
residu
appear
abl
make
similar
stabil
interact
figur
thu
optim
process
result
select
amino
acid
substitut
stabil
induc
fit
conform
cdr
loop
adopt
complex
ha
compar
mode
interact
broadli
neutral
antibodi
recogn
membran
proxim
fusion
domain
ha
crossgroup
neutral
antibodi
corti
et
al
dreyfu
et
al
nakamura
et
al
well
group
antibodi
ekiert
et
al
sui
et
al
recogn
helix
adjac
hydrophob
groov
figur
blue
box
contrast
group
antibodi
ekiert
et
al
friesen
et
al
recogn
differ
region
fusion
peptid
small
sheet
fusion
domain
figur
red
box
epitop
uniqu
among
crossgroup
neutral
antibodi
report
date
repres
combin
region
structur
comparison
habound
overlap
antibodi
shown
figur
reveal
overal
orient
sit
slightli
higher
ha
antibodi
lower
nearest
paratop
residu
membran
proxim
end
ha
antibodi
bind
similarli
residu
hydrophob
groov
adjac
helix
fusion
domain
antibodi
contain
four
amino
acid
sequenc
valpheglyvalil
otherwis
dissimilar
loop
tetrapeptid
superpos
complex
allatom
rootmeansquar
deviat
rmsd
indic
interact
cognat
similar
way
figur
howev
contact
made
antibodi
ha
quit
differ
reflect
fact
two
antibodi
particularli
similar
sequenc
deriv
differ
germlin
sequenc
vk
versu
contact
base
helix
fusion
peptid
loop
respect
figur
contrast
contact
made
heavi
chain
fab
mainli
involv
appear
buri
helix
use
three
light
chain
cdr
loop
consequ
interact
buri
total
achiev
similar
affin
smaller
buri
surfac
second
crossgroup
neutral
antibodi
structur
complex
group
report
first
although
recogn
group
group
higher
vivo
neutral
activ
group
virus
corti
et
al
crossgroup
bind
attribut
long
flexibl
accommod
differ
conform
environ
observ
group
group
virus
much
signific
rearrang
bound
ha
group
versu
ha
group
complex
ha
group
ha
group
overlap
close
figur
therefor
bind
similar
way
group
greater
structur
conserv
bind
interfac
like
respons
broader
neutral
abil
unmet
medic
need
effect
treatment
sever
influenza
potenti
broadli
infectivityneutr
antibodi
use
therapeut
address
need
provid
stimulu
isol
character
among
antibodi
consid
date
antiha
human
monoclon
antibodi
demonstr
signific
breadth
infectivityneutr
capac
react
influenza
antigen
subtyp
potent
neutral
divers
viru
strain
numer
ha
subtyp
block
infect
lethal
caus
influenza
virus
administ
day
challeng
viru
mice
day
post
challeng
ferret
highli
pathogen
viru
potenti
abil
overcom
unpredict
characterist
influenza
name
antigen
shift
result
diseas
pandem
period
antigen
drift
occur
emerg
antigen
novel
virus
major
advantag
candid
antiinfluenza
therapeut
antibodi
mechan
neutral
infect
involv
process
begin
end
infect
cycl
bind
antibodi
infect
viru
inhibit
hamedi
membran
fusion
requir
initi
infect
end
infect
antibodi
bind
precursor
block
cleavag
prevent
format
spread
newli
made
infecti
viru
addit
bind
display
surfac
infect
cell
result
recognit
lysi
compon
immun
system
nk
cell
macrophag
complement
multipl
mechan
exhibit
presum
combin
ensur
observ
effect
antibodi
treatment
infect
mice
ferret
epitop
recogn
consist
way
block
ha
function
membran
fusion
locat
epitop
describ
previous
influenza
groupspecif
crossreact
antibodi
broadli
reactiv
antibodi
howev
region
ha
interact
combin
previous
assign
group
specif
primarili
hydrophob
groov
adjac
helix
ha
ekiert
et
al
sui
et
al
group
specif
separ
part
fusion
peptid
near
n
terminu
ekiert
et
al
friesen
et
al
structur
character
bound
unbound
structur
also
highlight
coordin
movement
insert
hydrophob
grove
ha
well
rearrang
orient
glycan
attach
viru
allow
antibodi
bind
importantli
structur
complex
form
indic
locat
orient
bound
antibodi
similar
structur
conserv
abil
interact
region
ha
presum
result
effect
crossreact
comparison
structur
complex
form
previous
report
complex
form
crossreact
monoclon
antibodi
ha
nakamura
et
al
indic
two
antibodi
amino
acid
sequenc
vfgv
vfgi
loop
occupi
equival
posit
complex
conceiv
structur
share
compon
antibodi
might
use
prepar
immunogen
select
candid
molecul
basi
affin
tetrapeptid
note
recent
paper
describ
develop
comput
design
protein
bind
helix
stem
region
group
show
vitro
vivo
antivir
efficaci
koday
et
al
reconstruct
development
pathway
well
suggest
gener
broadli
reactiv
antibodi
may
requir
stepwis
stimul
group
follow
select
mutat
variant
group
inde
donor
born
possibl
lineag
prime
matur
multipl
exposur
hypothesi
strengthen
observ
uca
mab
neutral
high
potenc
strain
ie
uca
mutat
antibodi
lineag
repres
use
tool
design
stembas
immunogen
use
heterolog
primeboost
mode
prime
group
reactiv
naiv
b
cell
select
expand
also
crossreact
group
base
result
report
current
evalu
safeti
efficaci
adult
uncompl
influenza
infect
outpati
set
http
clinicaltrialsgov
prior
conduct
studi
patient
hospit
influenza
caus
type
strain
monoclon
antibodi
isol
memori
b
cell
previous
describ
pappa
et
al
traggiai
et
al
blood
donor
given
written
inform
consent
follow
approv
canton
ethic
committe
canton
ticino
switzerland
antibodi
modifi
revert
nongermlin
framework
amino
acid
chang
affin
improv
parsimoni
mutagenesi
cdr
supplement
experiment
procedur
recombin
ha
protein
express
purifi
previous
describ
benjamin
et
al
bind
antibodi
measur
elisa
stain
ha
transfect
cell
use
flow
cytometri
supplement
experiment
procedur
wildtyp
influenza
strain
coldadapt
ca
liveattenu
influenza
vaccin
virus
complet
viral
strain
design
shown
tabl
propag
embryon
chicken
egg
titer
use
infect
mdck
cell
determin
neutral
activ
describ
supplement
experiment
procedur
antibodymedi
fusion
inhibit
test
use
low
phinduc
red
blood
cell
fusion
model
adapt
protocol
describ
wang
et
al
abil
inhibit
low
phactiv
conform
chang
trypsindigest
ha
analyz
sdspage
abil
antibodi
block
cleavag
tpcktreat
trypsin
measur
western
blot
analysi
supplement
experiment
procedur
adcc
activ
measur
ldh
releas
assay
use
primari
human
nk
cell
effector
cell
influenza
viru
infect
cell
target
adcp
activ
measur
flow
cytometri
use
fluoresc
label
monocytederiv
macrophag
haexpress
mdck
target
cell
cdc
activ
measur
ldh
releas
assay
use
rabbit
complement
influenza
mdck
cell
supplement
experiment
procedur
anim
studi
approv
conduct
accord
medimmun
institut
anim
care
use
committe
murin
studi
southern
research
institut
institut
anim
care
use
committe
ferret
studi
perform
associ
assess
accredit
laboratori
anim
care
aaalac
certifi
facil
control
mab
administ
singl
intraperiton
ip
dose
variou
day
post
infect
depend
viru
strain
oseltamivir
comparison
studi
mice
administ
mgkg
oseltamivir
mouth
po
bid
day
singl
mgkg
dose
iv
vehicl
po
bid
day
viral
load
lung
measur
assay
day
post
infect
five
sixmonthold
ferret
challeng
intranas
viru
treat
singl
mgkg
iv
dose
control
oseltamivir
mgkg
bid
day
initi
differ
day
post
infect
biometr
data
system
chip
use
temperatur
monitor
supplement
experiment
procedur
purifi
viru
membran
mix
purifi
antibodi
fab
fragment
incub
overnight
complex
format
complex
purifi
sizeexclus
chromatographi
concentr
crystal
crystal
frozen
direct
immers
liquid
nitrogen
diffract
dataset
collect
k
beamlin
diamond
light
sourc
harwel
structur
solv
molecular
replac
refin
use
standard
protocol
macromolecular
structur
deposit
access
number
pdb
apo
pdb
complex
pdb
complex
crystallograph
statist
summar
tabl
supplement
experiment
procedur
bfr
carri
pcr
immunoglobulin
sequenc
b
cell
ga
produc
purifi
antibodi
mf
analyz
immunoglobulin
genet
element
produc
figur
carri
bioinformat
analysi
dp
cs
carri
donor
select
screen
identif
crossreact
antibodi
fv
af
carri
clone
test
antibodi
bind
cytofluorimetri
sb
perform
biochem
cellular
assay
test
fusion
ha
matur
inhibit
activ
isol
antibodi
bg
adm
carri
adcc
cdc
studi
fs
wrote
paper
al
dc
direct
b
cell
isol
studi
analyz
data
wrote
paper
jmm
eb
carri
vivo
studi
lwr
carri
adcp
studi
fjph
carri
elisa
bind
studi
nlk
qz
lwr
fjph
carri
neutral
studi
aqi
lead
antibodi
optim
ja
edit
paper
provid
supervis
nlk
qz
direct
antibodi
optim
vitro
vivo
character
analyz
data
wrote
paper
pjc
un
paw
mkv
rwo
srm
sjg
jj
design
perform
structur
research
contribut
new
reagent
analyt
tool
analyz
data
wrote
paper
al
scientif
founder
humab
biom
sa
al
hold
share
humab
biom
bg
adm
ga
fv
dc
employe
humab
biom
work
fund
medimmun
llc
wholli
own
subsidiari
astrazeneca
pharmaceut
nlk
jmm
eb
lwr
fjph
aqi
ja
qz
employ
medimmun
llc
work
execut
may
current
hold
astrazeneca
stock
stock
option
